Alterations in the gene expression of ependymomas

• Grant number: 12/15128-0
• Support Opportunities: Regular Research Grants
• Start date: November 01, 2012
• End date: October 31, 2014
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Sueli Mieko Oba Shinjo
• Grantee: Sueli Mieko Oba Shinjo
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Fernanda Goncalves de Andrade ; Hamilton Matushita ; Mario Augusto Taricco ; Miyuki Uno ; Sergio Rosemberg ; Suely Kazue Nagahashi Marie

Abstract

Ependymomas are tumors of neuroectodermic origin which derive from ependymal cells that cover the central canal of ventricles and the spinal cord. Ependymomas represent around 10% of central nervous system tumors and 25% of intramedullar tumors. Ependymomas accounts for 30% of primary intracranial neoplasias in children younger than 3 years, and they are the third most common tumor in pediatric patients. Spinal ependymomas are more common in patients of 15 to 40 year old. Ependymomas are classified according to the malignant grade in grade I, II or III and the molecular alterations that lead to the ependymoma oncogenesis are not yet completely known. Many casuistic have been published, but the management is still controversy among different institutions, which adopt as treatment only surgery or a combination of surgery, chemo and radiotherapy. The absence of a standard treatment and large population studies becomes difficult a better treatment of patients with this type of tumor. Although surgery plays a well-established role, the value of adjuvant treatments is still controversy. Therefore, a better understanding of ependymomas tumorigenesis is important to a better evaluation of the response for treatments and prognostic of patients. The aim of this work is to identify differentially expresses genes in ependymomas, to correlate the expression with data of patients, as age at diagnosis, localization and histologic type, as well as relapse and overall survival. Identification of prognostic markers which better defines the nature and differences of ependymomas are of extreme relevance for the search of new strategies for the treatment of patients. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DE SOUSA, GRAZIELLA RIBEIRO; NAGAHASHI MARIE, SUELY KAZUE; OBA-SHINJO, SUELI MIEKO; ZAMBELLI RAMALHO, LEANDRA NAIRA; TONE, LUIZ GONZAGA; VALERA, ELVIS TERCI. A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review. CHILD'S NERVOUS SYSTEM, v. 35, n. 4, p. 689-694, APR 2019. (14/20341-0, 12/15128-0)

DE ANDRADE, FERNANDA GONCALVES; NAGAHASHI MARIE, SUELY KAZUE; UNO, MIYUKI; MATUSHITA, HAMILTON; TARICCO, MARIO AUGUSTO; TEIXEIRA, MANOEL JACOBSEN; ROSEMBERG, SERGIO; OBA-SHINJO, SUELI MIEKO. Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases. NEUROPATHOLOGY, v. 35, n. 4, p. 312-323, AUG 2015. (12/15128-0)